{"log_id": 4431768604664129034, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0.000182, "average": 0.994974, "min": 0.922674}, "location": {"width": 822, "top": 158, "height": 56, "left": 236}, "words": "黑色素瘤皮肤癌(NMSC)。本品治疗患者中十分罕见 Merkel细胞癌的上市后报"}, {"probability": {"variance": 1e-06, "average": 0.999038, "min": 0.995458}, "location": {"width": 640, "top": 206, "height": 50, "left": 236}, "words": "告。推荐所有患皮肤癌风险增高的患者进行周期性的皮肤检查"}, {"probability": {"variance": 2e-06, "average": 0.998959, "min": 0.994121}, "location": {"width": 777, "top": 256, "height": 53, "left": 277}, "words": "在本品的临床试验中综合对照部分的结果发现,与对照组相比本品治疗组患"}, {"probability": {"variance": 1.7e-05, "average": 0.997165, "min": 0.986115}, "location": {"width": 484, "top": 302, "height": 47, "left": 231}, "words": "者产生NMSC的病例较多,尤其在银屑病患者"}, {"probability": {"variance": 8e-06, "average": 0.997711, "min": 0.992733}, "location": {"width": 99, "top": 353, "height": 29, "left": 228}, "words": "疫苗接种"}, {"probability": {"variance": 8.2e-05, "average": 0.997889, "min": 0.946783}, "location": {"width": 777, "top": 401, "height": 53, "left": 273}, "words": "本品治疗过程中严禁使用活疫苗。尚无接受本品治疗的患者由于接受活疫苗"}, {"probability": {"variance": 1e-06, "average": 0.999184, "min": 0.995535}, "location": {"width": 823, "top": 447, "height": 56, "left": 224}, "words": "而发生二次传播感染的资料。一项双盲、安慰剂对照的随机临床试验中,184例"}, {"probability": {"variance": 7e-06, "average": 0.998672, "min": 0.988874}, "location": {"width": 820, "top": 494, "height": 57, "left": 224}, "words": "成年银屑病关节炎患者在第4周接受了多价肺炎球菌多糖疫苗,多数接受本品治"}, {"probability": {"variance": 3e-06, "average": 0.999008, "min": 0.991841}, "location": {"width": 802, "top": 542, "height": 56, "left": 219}, "words": "疗的银屑病性关节炎患者能对肺炎球菌多糖疫苗产生有效的B细胞免疫应答"}, {"probability": {"variance": 0.00124, "average": 0.990571, "min": 0.797962}, "location": {"width": 822, "top": 589, "height": 57, "left": 219}, "words": "但是与未接受本品治疗的患者比较,总滴度略低,但少数患者滴度增加2倍,但"}, {"probability": {"variance": 5e-06, "average": 0.9987, "min": 0.993189}, "location": {"width": 218, "top": 637, "height": 38, "left": 216}, "words": "其临床意义尚不明确"}, {"probability": {"variance": 1e-06, "average": 0.998989, "min": 0.996786}, "location": {"width": 146, "top": 687, "height": 31, "left": 216}, "words": "自身抗体形成"}, {"probability": {"variance": 1e-06, "average": 0.999101, "min": 0.995731}, "location": {"width": 433, "top": 735, "height": 43, "left": 259}, "words": "本品治疗可能会产生自身抗体(参见“不"}, {"probability": {"variance": 0, "average": 0.999668, "min": 0.99913}, "location": {"width": 124, "top": 781, "height": 29, "left": 210}, "words": "血液学反应"}, {"probability": {"variance": 0, "average": 0.999716, "min": 0.999716}, "location": {"width": 64, "top": 748, "height": 50, "left": 928}, "words": "司"}, {"probability": {"variance": 0.011479, "average": 0.979697, "min": 0.373764}, "location": {"width": 773, "top": 828, "height": 54, "left": 258}, "words": "接受本品治疗的患者罕见报告出现全血细胞减少,十分罕见报出现再生障"}, {"probability": {"variance": 0.004337, "average": 0.980221, "min": 0.621763}, "location": {"width": 879, "top": 865, "height": 75, "left": 205}, "words": "碍性贫血,一些导致死亡。有血液质病史的患者使用本品治疗时,应谨慎使用"}, {"probability": {"variance": 0.001606, "average": 0.986205, "min": 0.783657}, "location": {"width": 820, "top": 920, "height": 58, "left": 204}, "words": "使用本品过程中,所有出现血恶液质或感染征兆(比如持续发热、咽喉痛、淤而"}, {"probability": {"variance": 0.00164, "average": 0.988703, "min": 0.770444}, "location": {"width": 826, "top": 967, "height": 62, "left": 203}, "words": "出血、苍白)的患者:应即寻求医疗指导。以上患者应当立即进行包括全血细"}, {"probability": {"variance": 0.000251, "average": 0.993456, "min": 0.921731}, "location": {"width": 624, "top": 1015, "height": 56, "left": 201}, "words": "胞计数在内的检查如果确诊血恶液质,必须停止使用本品"}, {"probability": {"variance": 1e-06, "average": 0.99879, "min": 0.996755}, "location": {"width": 193, "top": 1067, "height": 36, "left": 201}, "words": "中枢神经系统疾病"}, {"probability": {"variance": 0.000636, "average": 0.992176, "min": 0.872278}, "location": {"width": 776, "top": 1112, "height": 57, "left": 247}, "words": "罕见报告本品治疗的患者出现中枢神经系统脱髓鞘病变参见“不良反"}, {"probability": {"variance": 1.9e-05, "average": 0.99822, "min": 0.979721}, "location": {"width": 828, "top": 1159, "height": 57, "left": 195}, "words": "应”)。另外,有十分罕见的外周脱髓鞘性多发性神经病的报告(包括格林巴利"}, {"probability": {"variance": 4e-06, "average": 0.998301, "min": 0.992448}, "location": {"width": 825, "top": 1208, "height": 55, "left": 195}, "words": "综合征,慢性炎症性脱髓鞘性多发性神经病,脱髓鞘性多发性神经病和多灶性运"}, {"probability": {"variance": 3e-06, "average": 0.998924, "min": 0.990946}, "location": {"width": 826, "top": 1255, "height": 57, "left": 194}, "words": "动神经病)。虽然还没有本品用于多发性硬化症患者的临床试验,但其他TNF抑"}, {"probability": {"variance": 6e-05, "average": 0.997876, "min": 0.953281}, "location": {"width": 825, "top": 1303, "height": 56, "left": 191}, "words": "制剂对多发性硬化症患者的临床试验显示疾病活动性有所增加。当对曾经或正患"}, {"probability": {"variance": 2e-06, "average": 0.998969, "min": 0.995143}, "location": {"width": 827, "top": 1351, "height": 55, "left": 188}, "words": "有脱髓鞘疾病的患者或者被认为可能增加出现脱髓鞘疾病风险的患者开立处方"}, {"probability": {"variance": 3.2e-05, "average": 0.997803, "min": 0.973322}, "location": {"width": 632, "top": 1398, "height": 49, "left": 186}, "words": "时,应建议进行包括神经系统评估在内的详细风险/受益评估"}, {"probability": {"variance": 0, "average": 0.999755, "min": 0.999234}, "location": {"width": 98, "top": 1447, "height": 29, "left": 188}, "words": "联合治疗"}, {"probability": {"variance": 3e-06, "average": 0.998988, "min": 0.991589}, "location": {"width": 776, "top": 1494, "height": 54, "left": 234}, "words": "在类风湿关节炎患者中进行为期2年的对照临床试验表明,本品与甲氨蝶呤"}], "language": 3}